Cancer immunotherapy using immune checkpoint blockade (ICB), including antibodies blocking cytotoxic T lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 [PD-(L)1], has improved the outcomes of patients with cancer, although overall, only a minority benefit from the currently available ICB (1, 2). This evidence concerns the gene CTLA4 and cancer.